Терапия COVID-19: место антиревматических препаратов
Аннотация
В настоящее время пристальное внимание медицинского и мирового сообщества по-прежнему приковано к новой коронавирусной инфекции, которая стала причиной пандемии в 2020 г. Понимание глубинных механизмов коронавирусной болезни (Coronavirus disease-19 — COVID-19) дало возможность перейти от эмпирического подбора терапии, что наблюдалось в начале пандемии, к патогенетически обоснованному назначению препаратов, в том числе глюкокортикоидов, антикоагулянтов, некоторых противоревматических средств. Однако, несмотря на огромное количество накопленного за 1,5 года научного и клинического материала, интерес к указанной проблеме не ослабевает как из-за существования ряда нерешённых вопросов, так и вследствие постоянного появления новых (нередко, противоречивых) данных.
Об авторах
М. А. Литвинова
ФГБНУ Научно-исследовательский институт ревматологии им. В. А. Насоновой
Россия
Россия
Литвинова Мария Александровна — ординатор
Москва
Н. В. Муравьева
ФГБНУ Научно-исследовательский институт ревматологии им. В. А. Насоновой
Россия
Россия
Муравьева Наталья Валерьевна — к. м. н., научный сотрудник лаборатории изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии. ResearcherID: AAF-4853-2021. eLIBRARY SPIN-код: 8418-4469. Scopus Author ID: 57210263706
Москва
Б. С. Белов
ФГБНУ Научно-исследовательский институт ревматологии им. В. А. Насоновой
Россия
Россия
Белов Борис Сергеевич — д. м. н., заведующий лабораторией изучения коморбидных инфекций и мониторинга безопасности лекарственной терапии. ResearcherID: ABD-2219-2020. eLIBRARY SPIN-код: 3298-4315. Scopus Author ID: 7004592537
Каширское шоссе, 34-А, г. Москва, 115522
Список литературы
1. Kingsmore K.M., Grammer A.C., Lipsky P.E. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020; 16 (1): 32–52. doi: 10.1038/s41584-019-0337-0.
2. Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020; 58 (2): 123–132. doi: 10.14412/1995-4484-2020-123-132.
3. Based on currently available information, WHO does not recommend against the use of of ibuprofen. Available at: https://twitter.com/WHO/status/1240409217997189128.
4. Lund L.C., Kristensen K.B., Reilev M., Christensen S., Thomsen R.W., Christiansen C.F. et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med. 2020; 17 (9): e1003308. doi: 10.1371/journal.pmed.1003308.
5. Bruce E., Barlow-Pay F., Short R., Vilches-Moraga A., Price A., McGovern A. et al. Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19. J Clin Med. 2020; 9; 2586. doi: 10.3390/jcm9082586.
6. Robb C.T., Goepp M., Rossi A.G., Yao C. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020; 177 (21): 4899–4920. doi: 10.1111/bph.15206.
7. Strehl C., Ehlers L., Gaber T., Buttgereit F. Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019; 10: 1744. doi: 10.3389/fimmu.2019.01744.
8. Hardy R.S., Raza K., Cooper M.S. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020; 16 (3): 133–144. doi: 10.1038/s41584-020-0371-y.
9. Veronese N., Demurtas J., Yang L., Tonelli R., Barbagallo M., Lopalco P. et al. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. Front Med (Lausanne). 2020; 7: 170. doi: 10.3389/fmed.2020.00170.
10. WHO. Clinical management of severe acute respiratory infection when novel coronavirus [nCoV] infection is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-[ncov]-infection-is-suspected (accessed 09.02.2020).
11. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 934–943. doi: 10.1001/jamainternmed.2020.0994.
12. Wang Y., Jiang W., He Q., Wang C., Wang B., Zhou P. et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020; 5 (1): 57. doi: 10.1038/s41392-020-0158-2.
13. Ranjbar K., Moghadami M., Mirahmadizadeh A., Fallahi M.J., Khaloo V., Shahriarirad R. et al. Methylprednisolone or dexamethasone, with one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021; 21 (1): 436. doi: 10.1186/s12879-021-06130-7.
14. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L. et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020: NEJMoa2021436. doi: 10.1056/NEJMoa2021436.
15. Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A Meta-analysis. JAMA. 2020; 324 (13): 1330–1341. doi: 10.1001/jama.2020.17023.
16. Keller M.J., Kitsis E.A., Arora S., Chen J-T., Agarwal S., Ross M.J. et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med. 2020; 8; 489–493. doi: 10.12788/jhm.3497.
17. Cano E.J., Fonseca Fuentes X., Corsini Campioli C., O'Horo J.C., Abu Saleh O., Odeyemi Y. et al. Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis. Chest. 2021 Mar; 159 (3): 1019–1040. doi: 10.1016/j.chest.2020.10.054.
18. Raju R., V. P., Biatris P.S., Chander S.J.U. Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials. Futur J Pharm Sci. 2021; 7 (1): 67. doi: 10.1186/s43094-021-00217-3.
19. Насонов Е.Л. Иммунофармакология и иммунофармакотерапия коронавирусной болезни 2019 (COVID-19): фокус на интерлейкин 6. Научно-практическая ревматология. 2020; 58 (3): 245–261. doi: 10.14412/1995-4484-2020-245-261.
20. Levi M. Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. Eur J Intern Med. 2020; 76: 21–22. doi: 10.1016/j.ejim.2020.05.018.
21. Salama C., Han J., Yau L., Reiss W.G., Kramer B., Neidhart J.D. et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021; 384 (1): 20–30. doi: 10.1056/NEJMoa2030340.
22. Моисеев С.В., Авдеев С.Н., Тао Е.А., Бровко М.Ю., Яворовский А.Г., Умбетова К.Т. и др. Эффективность тоцилизумаба у пациентов с COVID-19, госпитализированных в ОРИТ: ретроспективное когортное исследование. Клиническая фармакология и терапия. 2020; 29 (4): 17–25.
23. Gupta S., Wang W., Hayek S.S., Chan L., Mathews K.S., Melamed M.L. et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021; 181 (1): 41–51. doi: 10.1001/jamainternmed.2020.6252.
24. Narain S., Stefanov D.G., Chau A.S., Weber A.G., Marder G., Kaplan B. et al. Northwell COVID-19 research consortium. Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm. Chest. 2021 Mar; 159 (3): 933–948. doi: 10.1016/j.chest.2020.09.275.
25. Rezaei S., Fatemi B., Karimi Majd Z., Minaei H., Peikanpour M., Anjidani N. et al. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A systematic review and meta-analysis. Expert Rev Clin Immunol. 2021 May; 17 (5): 499–511. doi: 10.1080/1744666X.2021.1908128.
26. Hariyanto T.I., Hardyson W., Kurniawan A. efficacy and safety of tocilizumab for coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Drug Res (Stuttg). 2021 May; 71 (5): 265–274. doi: 10.1055/a-1336-2371.
27. Mantovani A., Dinarello C.A., Molgora M., Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019; 50 (4): 778–795. doi: 10.1016/j.immuni.2019.03.012.
28. Aouba A., Baldolli A., Geffray L., Verdon R., Bergot E., Martin-Silva N. et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020; 79 (10): 1381–1382. doi: 10.1136/annrheumdis-2020-217706.
29. Kyriazopoulou E., Panagopoulos P., Metallidis S., Dalekos G.N., Poulakou G., Gatselis N. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021; 10: e66125. doi: 10.7554/eLife.66125.
30. Bozzi G., Mangioni D., Minoia F., Aliberti S., Grasselli G., Barbetta L. et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. J Allergy Clin Immunol. 2021; 147 (2): 561–566. doi: 10.1016/j.jaci.2020.11.006.
31. Pontali E., Volpi S., Signori A., Antonucci G., Castellaneta M., Buzzi D. et al. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. J Allergy Clin Immunol. 2021; 147 (4): 1217–1225. doi: 10.1016/j.jaci.2021.01.024.
32. Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C. et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377 (12): 1119–1131. doi: 10.1056/NEJMoa1707914.
33. Diurno F., Numis F.G., Porta G., Cirillo F., Maddaluno S., Ragozzino A. et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020; 24 (7): 4040-4047. doi: 10.26355/eurrev_202004_20875.
34. Richardson P., Griffin I., Tucker C., Smith D., Oechsle O., Phelan A. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395 (10223): e30-e31. doi: 10.1016/S0140-6736(20)30304-4.
35. Cantini F., Niccoli L., Matarrese D., Nicastri E., Stobbione P., Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020; 81 (2): 318–356. doi: 10.1016/j.jinf.2020.04.017.
36. Kalil A.C., Patterson T.F., Mehta A.K., Tomashek K.M., Wolfe C.R., Ghazaryan V. et al. Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19. N Engl J Med. 2020: 384 (9): 795–807. doi: 10.1056/NEJMoa2031994.
37. Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19.Доступно по ссылке: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fdaauthorizes-drug-combination-treatment-covid-19?utm_medium=email&utm_source=govdelivery
38. Rodriguez-Garcia J.L., Sanchez-Nievas G., Arevalo-Serrano J., GarciaGomez C., Jimenez-Vizuete J.M., Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARSCoV-2 pneumonia: an observational cohort study. Rheumatology (Oxford). 2021; 60 (1): 399–407. doi: 10.1093/rheumatology/keaa587.
39. Chen C-Х., Wang J-J., Li H., Yuan L-T., Gale R.P., Liang Y. et al. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis. Leukemia. 2021; 35 (9): 2616–2620. doi: 10.1038/s41375-021-01266-6.
40. Deftereos S.G., Giannopoulos G., Vrachatis D.A., Siasos G.D., Giotaki S.G., Gargalianos P. et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial. JAMA Netw Open. 2020; 3 (6): e2013136. doi: 10.1001/jamanetworkopen.2020.13136.
41. Lopes M.I., Bonjorno L.P., Giannini M.C., Amaral N.B., Menezes P.I., Dib S.M. et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021 Feb; 7 (1): e001455. doi: 10.1136/rmdopen-2020-001455.
42. Chen Z., Hu J., Zhang Z., Jiang S., Han S., Yan D. et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. doi: 10.1101/2020.03.22.20040758.
43. Gao J., Tian Z., Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14 (1): 72–73. doi: 10.5582/bst.2020.01047.
44. Gbinigie K., Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open. 2020; 4 (2): bjgpopen20X101069. doi: 10.3399/bjgpopen20X101069.
45. Ferner R.E., Aronson J.K. Chloroquine and hydroxychloroquine in COVID-19. BMJ. 2020; 369: m1432. doi: 10.1136/bmj.m1432.
46. Shah S., Das S., Jain A., Misra D.P., Negi V.S. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis. 2020; 23 (5): 613–619. DOI: 10.1111/1756-185X.13842.
47. Mathian A., Mahevas M., Rohmer J., Roumier M., Cohen-Aubart F., AmadorBorrero B. et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under longterm treatment with hydroxychloroquine. Ann Rheum Dis. 2020; 79: 837–839. doi: 10.1136/annrheumdis-2020-217566.
48. Konig M.F., Kim A.H., Scheetz M.H., Graef E.R., Liew J.W., Simard J. et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020; 79 (10): 1386–1388. doi: 10.1136/annrheumdis-2020-217690.
49. Boulware D.R., Pullen M.F., Bangdiwala A.S., Pastick K.A., Lofgren S.M., Okafor E.C. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020; 383 (6): 517–525. doi: 10.1056/NEJMoa2016638.
50. Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate, 6/15/2020. Available at: https:www.fda.gov/media/138945/download
51. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия 11 (07.05.2021). Доступно на сайте: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/B%D0%9C%D0%A0_COVID-19.pdf.
Рецензия
Для цитирования:
Литвинова М.А., Муравьева Н.В., Белов Б.С. Терапия COVID-19: место антиревматических препаратов. Антибиотики и Химиотерапия. 2021;66(7-8):83-89. https://doi.org/10.37489/0235-2990-2021-66-7-8-83-89
For citation:
Litvinova M.A., Muravyeva N.V., Belov B.S. COVID-19 Therapy: the Role of Antirheumatic Drugs. Antibiotics and Chemotherapy. 2021;66(7-8):83-89. (In Russ.) https://doi.org/10.37489/0235-2990-2021-66-7-8-83-89
Просмотров: 323
Послать статью по эл. почте 